Alpine Global Management’s Adverum Biotechnologies ADVM Stock Holding History

Alpine Global Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,305	Closed	-$28K	–	770
2021 Q3	$28K	Buy	+1,305	New	+$33.3K	0.01%	289
2018 Q1	–	Sell	-2,071	Closed	-$72K	–	116
2017 Q4	$72K	Buy	+2,071	New	+$68.1K	0.02%	173

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Alpine Global Management's ADVM Position: Q4 2021 in Review

Alpine Global Management sold out of Adverum Biotechnologies (ADVM) in Q4 2021, closing a stake of 1,305 shares — an estimated $28K sold.

Alpine Global Management first reported a position in ADVM in Q4 2017 and held it in 2 quarters. The position peaked at $72K in Q4 2017. 98 funds tracked by Wall St. Rank hold ADVM as of Q4 2021.

Alpine Global Management reported no remaining Adverum Biotechnologies position as of Q4 2021 after selling out during the quarter.
Alpine Global Management sold 1,305 Adverum Biotechnologies shares in Q4 2021, an estimated $28K.
Alpine Global Management first reported a position in Adverum Biotechnologies in Q4 2017 and held it in 2 quarters.
Alpine Global Management's Adverum Biotechnologies position peaked at $72K in Q4 2017.
98 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2021.

Based on Alpine Global Management's 13F filing for Q4 2021, filed 14 Feb 2022.